Spyre Therapeutics (SYRE) Research & Development (2015 - 2026)
Spyre Therapeutics (SYRE) posted Research & Development of $60.4 million for Q1 2026, up 35.34% on a QoQ basis from $44.6 million in Q4 2025, and up 45.14% year-over-year from $41.6 million in Q1 2025.
Spyre Therapeutics (SYRE) Research & Development (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Research & Development history runs 12 years deep, the most recent figure standing at $60.4 million for Q1 2026.
- Quarterly Research & Development rose 45.14% year-over-year to $60.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.4 million (up 12.36% YoY) and the FY2025 annual result came in at $171.7 million, up 5.44% from the prior year.
- Research & Development was $60.4 million for Q1 2026 at Spyre Therapeutics, up from $44.6 million in the prior quarter.
- Across five years, Research & Development topped out at $60.4 million in Q1 2026 and bottomed at $12.0 million in Q3 2022.
- A 5-year average of $31.9 million and a median of $33.7 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development slipped 19.36% — and 2024, when it surged 153.54%.
- Spyre Therapeutics' Research & Development stood at $14.3 million in 2022, then surged by 136.35% to $33.7 million in 2023, then surged by 49.88% to $50.5 million in 2024, then dropped by 11.58% to $44.6 million in 2025, then soared by 35.34% to $60.4 million in 2026.
- Business Quant data shows SYRE's Research & Development at $60.4 million in Q1 2026, $44.6 million in Q4 2025, and $45.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | 60.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.41 Mn |
| Dec 31, 2025 | 44.64 Mn |
| Sep 30, 2025 | 45.25 Mn |
| Jun 30, 2025 | 40.15 Mn |
| Mar 31, 2025 | 41.62 Mn |
| Dec 31, 2024 | 50.48 Mn |
| Sep 30, 2024 | 44.74 Mn |
| Jun 30, 2024 | 32.64 Mn |
| Mar 31, 2024 | 34.93 Mn |
| Dec 31, 2023 | 33.68 Mn |
| Sep 30, 2023 | 24.66 Mn |
| Jun 30, 2023 | 17.39 Mn |
| Mar 31, 2023 | 13.78 Mn |
| Dec 31, 2022 | 14.25 Mn |
| Sep 30, 2022 | 11.98 Mn |
| Jun 30, 2022 | 15.37 Mn |
| Mar 31, 2022 | 16.98 Mn |
| Dec 31, 2021 | 16.78 Mn |
| Sep 30, 2021 | 14.85 Mn |
| Jun 30, 2021 | 13.58 Mn |